XSTO
NNH
Market cap11mUSD
Oct 09, Last price
18.10SEK
1D
1.11%
1Q
48.57%
Jan 2017
-33.82%
IPO
-63.96%
Name
New Nordic Healthbrands AB
Chart & performance
P/E
13.68
P/S
0.19
EPS
1.32
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
5.07%
Revenues
576m
+4.73%
Net income
8m
P
CFO
8m
P
Dividend
Apr 30, 20260.25 SEK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
New Nordic Healthbrands AB (publ)., engages in providing dietary supplements, natural medicines and cosmetic products for various health and beauty needs in the Nordic countries, Europe, North America, and internationally. The company provides vitality tablets, capsules, and gummy products, including vitamins and minerals, fish oil and Omega-3, and magnesium, as well as for body, sleep and relaxation, menopause, and men health; skincare products comprising dietary supplements, facial care, and body care, as well as assortment products; hair care products, such as hair volume products, dietary supplements, shampoos, conditioners, serum, and other hair care products; and weight loss products. The company sells its products through pharmacies, health stores,beauty stores, and travel retailers, as well as through online stores. New Nordic Healthbrands AB (publ) was founded in 1990 and is headquartered in Malmö, Sweden.
Key people
Ivan Ruscic
Chief Financial Officer · since 2020
Tage Finninge
Chief Commercial and Operating Officer · since 2023
Chairman of the Board · since 2025
Karl Bergman Jensen
Chief Executive Officer, Director
Marinus Blabjerg Soerensen
Director · since 2023
Carina Brorman
Director · since 2024
Lennart Sjolund
Independent Director · since 2025
Headquarters & legal address
SÖDRA FÖRSTADSGATAN 3
SKÅNE LÄN
MALMÖ, M 211 43
SE
SKÅNE LÄN
MALMÖ, M 211 43
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||